Yunhong Zha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yunhong Zha has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Han-Fei Ding
University of Alabama at Birmingham 1 Department of Pathology, Heersink School of Medicine Birmingham, Alabama
49 shared publications - Yajie Yu
Institute of Neural Regeneration and Repair and Department of Neurology, The First Hospital of Yichang, Three Gorges University College of Medicine, Yichang, China
47 shared publications - Zheng Dong
Augusta University
47 shared publications - Bingwei Ye
Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, Georgia
46 shared publications - Gia-Buu Tran
Research Group in Pharmaceutical and Biomedical Sciences, Faculty of Pharmacy Ton Duc Thang University Ho Chi Minh City Vietnam
46 shared publications - Jane Ding
University of Alabama at Birmingham 1 Department of Pathology, Heersink School of Medicine Birmingham, Alabama
46 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
GO analysis of genes down-regulated by simvastatin
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
GO analysis of genes down-regulated by simvastatin
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
Go analysis of genes up-regulated by simvastatin
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
Go analysis of genes up-regulated by simvastatin
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
GO analysis of genes up-regulated in the Simvastatin plus mevalonate group vs. the simvastatin group.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
GO analysis of genes up-regulated in the Simvastatin plus mevalonate group vs. the simvastatin group.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
High-risk neuroblastoma exhibits transcriptional activation of the mevalonate pathway that produces cholesterol and nonsterol isoprenoids. A better understanding of how this metabolic reprogramming contributes to neuroblastoma development could help identify potential prevention and treatment strategies. Here, we report that both the cholesterol and nonsterol geranylgeranyl-pyrophosphate branches of the mevalonate pathway are critical to sustain neuroblastoma cell growth. Blocking the mevalonate pathway by simvastatin, a cholesterol-lowering drug, impeded neuroblastoma growth in neuroblastoma cell line xenograft, patient-derived xenograft (PDX), and TH-MYCN transgenic mouse models. Transcriptional profiling revealed that the mevalonate pathway was required to maintain the FOXM1-mediated transcriptional program that drives mitosis. High FOXM1 expression contributed to statin resistance and led to a therapeutic vulnerability to the combination of simvastatin and FOXM1 inhibition. Furthermore, caffeine synergized with simvastatin to inhibit the growth of neuroblastoma cells and PDX tumors by blocking statin-induced feedback activation of the mevalonate pathway. This function of caffeine depended on its activity as an adenosine receptor antagonist, and the A2A adenosine receptor antagonist istradefylline, an add-on drug for Parkinson's disease, could recapitulate the synergistic effect of caffeine with simvastatin. This study reveals that the FOXM1-mediated mitotic program is a molecular statin target in cancer and identifies classes of agents for maximizing the therapeutic efficacy of statins, with implications for treatment of high-risk neuroblastoma.Significance:Caffeine treatment and FOXM1 inhibition can both enhance the antitumor effect of statins by blocking the molecular and metabolic processes that confer statin resistance, indicating potential combination therapeutic strategies for neuroblastoma.See related commentary by Stouth et al., p. 2091
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Caffeine Supplementation and FOXM1 Inhibition Enhance the Antitumor Effect of Statins in Neuroblastoma
High-risk neuroblastoma exhibits transcriptional activation of the mevalonate pathway that produces cholesterol and nonsterol isoprenoids. A better understanding of how this metabolic reprogramming contributes to neuroblastoma development could help identify potential prevention and treatment strategies. Here, we report that both the cholesterol and nonsterol geranylgeranyl-pyrophosphate branches of the mevalonate pathway are critical to sustain neuroblastoma cell growth. Blocking the mevalonate pathway by simvastatin, a cholesterol-lowering drug, impeded neuroblastoma growth in neuroblastoma cell line xenograft, patient-derived xenograft (PDX), and TH-MYCN transgenic mouse models. Transcriptional profiling revealed that the mevalonate pathway was required to maintain the FOXM1-mediated transcriptional program that drives mitosis. High FOXM1 expression contributed to statin resistance and led to a therapeutic vulnerability to the combination of simvastatin and FOXM1 inhibition. Furthermore, caffeine synergized with simvastatin to inhibit the growth of neuroblastoma cells and PDX tumors by blocking statin-induced feedback activation of the mevalonate pathway. This function of caffeine depended on its activity as an adenosine receptor antagonist, and the A2A adenosine receptor antagonist istradefylline, an add-on drug for Parkinson's disease, could recapitulate the synergistic effect of caffeine with simvastatin. This study reveals that the FOXM1-mediated mitotic program is a molecular statin target in cancer and identifies classes of agents for maximizing the therapeutic efficacy of statins, with implications for treatment of high-risk neuroblastoma.Significance:Caffeine treatment and FOXM1 inhibition can both enhance the antitumor effect of statins by blocking the molecular and metabolic processes that confer statin resistance, indicating potential combination therapeutic strategies for neuroblastoma.See related commentary by Stouth et al., p. 2091
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma
GO analysis of genes down-regulated by simvastatin
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma
GO analysis of genes down-regulated by simvastatin
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma
GO analysis of genes up-regulated in the Simvastatin plus mevalonate group vs. the simvastatin group.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma
GO analysis of genes up-regulated in the Simvastatin plus mevalonate group vs. the simvastatin group.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma
Supplementary Table S2 from Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma
Supplementary Table S2 from Caffeine supplementation and FOXM1 inhibition enhance the antitumor effect of statins in neuroblastoma